The data shows that due to the high base of the epidemic in 2020, short-term financial and other factors, the growth rate of the pharmacy industry continued to decline
in the second half of 2021.
However, from the first half of 2022, the revenue and profit growth rate of the pharmacy sector began to recover
.
Among them, the single-quarter revenue of the pharmacy sector from 22Q1 to 22Q2 was 20.
39/22.
38 billion yuan, an increase of 16.
9%/27% year-on-year; Net profit attributable to the mother was 1.
16/1.
24 billion yuan, an increase of -1.
7%/9% year-on-year; Net profit after deduction of non-attributable to the mother was 1.
14/1.
18 billion yuan, an increase of 1.
6%/11.
7%
year-on-year.
The industry believes that the performance of the pharmacy sector in the first half of the year is mainly due to the effective prevention and control of the epidemic and the gradual cancellation
of the restriction on the sale of "four types of drugs" in pharmacies.
According to Zhongkang CMH data, the sales of the national retail pharmacy industry in 2022Q1 and Q2 increased by 3.
0% and 4.
2%
respectively year-on-year.
In the first half of the year, in addition to the overall improvement of the industry, in fact, the upward trend of the performance inflection point of the leading chain pharmacies in 2022 is also very clear
.
For example, on the evening of August 29, the People's Pharmacy released a semi-annual report showing that H1 Company achieved revenue of 8.
991 billion yuan, an increase of 20.
51% year-on-year; Achieved net profit attributable to the mother of 457 million yuan, an increase of 12.
48%
year-on-year.
Compared with the Q1 net profit increased by 6.
26% year-on-year, the company's Q2 net profit increased by 20.
41% year-on-year, and the
month-on-month growth rate is rising.
On the same day, Shuyu Civilian also released the 2022 semi-annual report, saying that during the reporting period, the company achieved revenue of 3.
390 billion yuan, an increase of 36.
73% year-on-year, achieved a net profit attributable to the mother of 112 million yuan, an increase of 28.
26% year-on-year, and deducted non-net profit of 106 million yuan, an increase of 33.
57% year-on-year.
From the overall point of view, since 2022Q1, the growth of chain pharmacies in the same store has been improving month by month, and the recovery trend after the epidemic is clear
.
It is worth noting that the increase in the concentration of chain pharmacies is the core logic of the
industry, and from the current point of view, the leading pharmacies in Yeji continue to improve at the same time, and the "horse racing" is also underway.
Since 2022, listed pharmacies have been staging large-scale acquisitions
.
According to the previous plans of some listed chain pharmacies, the "era of ten thousand stores" has accelerated
.
It is understood that on June 26, the People's Pharmacy announced the opening of the 10,000th store, which is the first private listed chain pharmacy enterprise
in China with a number of stores exceeding 10,000.
As of the end of March this year, the people had 8612 stores, that is to say, in less than three months, the people added 1388 new
stores.
In addition, as of the end of March this year, Yifeng Pharmacy also has 8225 stores (a net increase of 416 stores in the first quarter), 8469 stores in Dashenlin (a net increase of 276 stores in the first quarter), and 8809 stores directly operated by Yixintang (a net increase of 249 stores in the first quarter).
In addition, Sinopharm also said some time ago that there are more than 9,000 NUS pharmacy stores
.
It is worth noting that with the expansion of the business coverage of the head pharmacy, the areas where the additional stores of various pharmacy brands are located are constantly overlapping
.
In this regard, the industry expects that while the number of listed chain pharmacies continues to grow, brand competition will become more and more intense
.
In general, under the expectation of gradual stabilization of prevention and control in the second half of the year and lifting of drug restrictions, analysts believe that pharmacies will gradually get rid of the repeated impact of the epidemic, and the growth rate of leading companies in the industry is expected to continue to improve in the second half of the year, revenue growth can be expected, and profit margins are expected to remain at a high level
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
